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1. INTRODUCTION {#cam43287-sec-0005}
===============

As the fourth most frequently diagnosed cancer and the fourth leading cause of cancer‐related death, cervical cancer (CC) accounted for 570,000 new cases and 311,000 deaths in 2018 worldwide.[^1^](#cam43287-bib-0001){ref-type="ref"} In China, CC is responsible for 18.4% of cancer‐related deaths in women.[^2^](#cam43287-bib-0002){ref-type="ref"} Radical hysterectomy with bilateral pelvic lymph node dissection via minimally invasive surgery (MIS) or laparotomy has been considered the standard treatment for early stage CC for decades.[^3^](#cam43287-bib-0003){ref-type="ref"} However, the effect of the surgical approach on survival outcomes remains controversial.

MIS has consistently been shown to produce similar survival outcomes to laparotomy group, but results in shorter hospital stays and a lower risk of operative morbidity.[^4^](#cam43287-bib-0004){ref-type="ref"}, [^5^](#cam43287-bib-0005){ref-type="ref"}, [^6^](#cam43287-bib-0006){ref-type="ref"}, [^7^](#cam43287-bib-0007){ref-type="ref"}, [^8^](#cam43287-bib-0008){ref-type="ref"} Nevertheless, a phase III randomized controlled trial, "Laparoscopic Approach to Carcinoma of Cervix (LACC)", identified an association of MIS with inferior disease‐free survival (DFS) and overall survival (OS) to open surgery.[^9^](#cam43287-bib-0009){ref-type="ref"} This trial triggered extensive discussion in clinical practice and prompted many new studies. Kim et al[^10^](#cam43287-bib-0010){ref-type="ref"} concluded that MIS was linked to higher recurrence rates than laparotomy in patients with stage IB1‐IIA2 CC, but was not a poor prognostic factor for patients with a tumor size ≤ 2 cm diagnosed with stage IB1 CC. In contrast, Cusimano et al[^11^](#cam43287-bib-0011){ref-type="ref"} reported poorer survival outcomes of MIS in the stage IB cohort, whereas no difference between MIS and laparotomy was identified in patients with other stages. Notably, the short‐term benefits of MIS had also been questioned. According to a recent study by a Chinese group, MIS is associated with a higher risk of major surgical complications than open surgery.[^12^](#cam43287-bib-0012){ref-type="ref"} Despite the many disputable findings on MIS, an analysis of possible contributing factors, such as surgeon proficiency, different medical circumstances among countries, etc, is lacking. Moreover, subgroup analyses of intermediate/high‐risk factors, such as histology, deep stromal invasion (DSI) and lymphovascular invasion (LVSI), are still lacking. Thus, additional solid evidence, particularly from multicenter larger cohort studies, is urgently needed to evaluate the effect of the surgical approach on survival outcomes.

To our knowledge, the largest sample size analyzed in this research area to date was 2461 in a study conducted in the United States.[^13^](#cam43287-bib-0013){ref-type="ref"} However, the evidence from populous Asian countries, such as China, particularly studies with a large sample size in high‐volume Chinese hospitals, is still lacking. Therefore, in the present study, we conducted a retrospective real‐world matched cohort study in four tertiary hospitals in China. We aimed to compare the survival outcomes of MIS and laparotomy and perform a comprehensive subgroup analysis of different combinations of various risk factors; we also aimed to assess the surgery trends and the effect of surgeon proficiency on survival outcomes. Moreover, we also determined the prognostic factors for RFS (recurrence‐free survival) and OS in our study population. Our study is the first to investigate the effect of the surgical approach in combination with multiple risk factors on survival outcomes in the largest sample size analyzed to date, which will provide additional evidence supporting the findings from previous studies and extend our understanding of surgical approach‐related survival outcomes in the real‐world setting.

2. MATERIALS AND METHODS {#cam43287-sec-0006}
========================

This retrospective multicenter cohort study was approved by the Institutional Ethics Committee of Fudan University Obstetrics and Gynecology Hospital (2019‐87). This study was registered in the Chinese Clinical Trial Registry (ChiCTR1900028702).

2.1. Study population {#cam43287-sec-0007}
---------------------

We identified patients with 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IA1 (LVSI) to IIA1 CC who underwent radical hysterectomy according to the classification proposed by Querleu and Morrow[^14^](#cam43287-bib-0014){ref-type="ref"} from January 2006 to December 2017 in four tertiary hospitals as study population. Patients received type B or C radical hysterectomy based on different stages in accordance with the National Comprehensive Cancer Network (NCCN) guidelines at the time.[^15^](#cam43287-bib-0015){ref-type="ref"}, [^16^](#cam43287-bib-0016){ref-type="ref"} The exclusion criteria were as follows: (1) pregnant women, (2) \<18 years old, (3) patients who received neoadjuvant therapy, (4) had a preexisting history of chemotherapy or radiotherapy for other conditions, (5) had a prior malignancy, (6) had an unclear lymphadenectomy status, (7) converted to laparotomy during the operation, and (8) had incomplete medical records or follow‐up data. In total, 3986 patients were enrolled in our study. 813 (20.4%) patients underwent laparotomy and 3173 (79.6%) received MIS. Patients who received robot‐assisted radical hysterectomy (RRH) or laparoscopic‐assisted radical vaginal hysterectomy (LARVH) were categorized into the MIS group for the intention‐to‐treat analysis. Of the 3173 patients who underwent MIS, 2956 (74.2%) received laparoscopic radical hysterectomy (LRH), 214 (5.4%) received RRH and 3 patients received LARVH.

2.2. Data collection {#cam43287-sec-0008}
--------------------

The retrospective data were obtained from four tertiary hospitals in Shanghai, China. All these hospitals were obstetrics and gynecology hospitals affiliated with a university. All medical records were reviewed simultaneously by three experts and independently checked by two experts to ensure the accuracy.

According to the NCCN guideline, preoperative workup for patients with suspicious symptoms includes history, physical examination, cervical cytologic screening, blood routine test (including platelets), liver and renal function, ECG, and imaging examinations. Radiologic imaging includes chest X‐ray, pelvic CT/MRI, or combined PET‐CT as indicated.[^17^](#cam43287-bib-0017){ref-type="ref"}, [^18^](#cam43287-bib-0018){ref-type="ref"} Cone biopsy is used if the cervical biopsy is inadequate to define invasiveness or if accurate assessment of microinvasive disease is required. When patients were older than 60, echocardiography, pulmonary function test and urodynamic test are also needed.

All patients underwent modified radical hysterectomy or radical hysterectomy with bilateral pelvic lymphadenectomy with or without para‐aortic lymphadenectomy according to NCCN guidelines. Before 2013, patients with IA1 (LVSI) received type B radical hysterectomy and patients with stage IA2‐IIA1 received type C radical hysterectomy. However, during 2013‐2017, patients with IA1 (LVSI) and IA2 underwent type B surgery, while those with IB1‐IIA1 underwent type C surgery. We began sentinel lymph node mapping in October 2016 by injecting 2‐4 ml methylene blue (MB) into the cervix (mainly at 2, 4, 8, and 10 o\'clock position) before surgery. All blue nodes were considered sentinel nodes through intraoperative direct inspection. At out institution, we have used the uterine manipulator (RUMI, CooperSurgical, Inc, Trumbull, CT) during 2005‐2017 and have strictly followed the tumor‐free principle during surgical procedure. For type B radical hysterectomy, the vagina is transected such that a 2‐cm upper vaginal margin is included with the surgical specimen. For type C radical hysterectomy, the upper 1/4‐1/3 of vagina should be included. Surgeon characteristics were derived from the physician database of Fudan University Obstetrics and Gynecology Hospital. Surgeon proficiency was classified as skilled (≥50) and unskilled (\<50) group according to the number of radical hysterectomies performed by the patient\'s surgeon in the 1 year prior to the patient\'s surgery year. These definitions ensured that surgeon proficiency could dynamically change over time.[^19^](#cam43287-bib-0019){ref-type="ref"}

Patients were treated with adjuvant treatment after radical hysterectomy when they met one of the following two criteria: a) patients who presented any one of several high‐risk factors (positive surgical margin, parametrial involvement, and lymph node (LN) metastasis) and b) Sedlis et al[^20^](#cam43287-bib-0020){ref-type="ref"} criteria were satisfied for intermediate‐risk factors (tumor size, LVSI, and DSI). After hospital discharge, patients received regular follow‐up in accordance with the NCCN guidelines.[^3^](#cam43287-bib-0003){ref-type="ref"} The median follow‐up time was 90 (18‐162) months.

2.3. Variables and outcomes {#cam43287-sec-0009}
---------------------------

All 18 variables were categorized into 6 clinical, 5 surgical and 7 pathological variables (Table [S1](#cam43287-sup-0006){ref-type="supplementary-material"}). Lymph node metastasis was classified as no metastases, pelvic LNs common iliac LNs and para‐aortic LNs. If metastases were observed in two or more locations, then the furthest LNs station will be marked. For example, the patients with positive para‐aortic LNs and pelvic LN metastases will be classified as positive para‐aortic LNs.

The primary outcomes were RFS and OS, including 2‐ and 5‐year rates. RFS was defined as the interval from the initial CC diagnosis to the first finding of any recurrence or last follow‐up. OS was defined as the interval from the initial diagnosis to the CC‐related death or last follow‐up. Patients who failed to reach the survival events at the last follow‐up were censored. Local recurrences were defined by pathologic proof of cancer in the vagina/cervix which were confined to the pelvis or an imaging study showing regrowth of tumor or enlargement of any pelvic lymph node. Distant recurrences were also defined by pathologic, cytologic, or radiologic evidence. Any recurrence out of the pelvis, including peritoneal spread, involvement of supraclavicular lymph nodes, lung, liver, bone, brain, etc The definition of local or distant recurrence was determined by the lesions detected at the time of first relapse after a complete workup.

2.4. Statistical analysis {#cam43287-sec-0010}
-------------------------

Continuous variables were reported as medians with interquartile ranges (IQRs) or means with standard deviations (SDs). Categorical variables were reported as number and proportions. We used Student\'s t‐test to compare continuous variables and Fisher\'s exact test or the χ^2^ test to compare categorical variables. The collinearity of all variables was evaluated using correlation matrices, and no significant interaction was identified. The Kaplan‐Meier method with the log‐rank test was used to compare survival outcomes. The associations of variables with RFS and OS were evaluated using Cox proportional hazards regression models. Hazard ratios (HRs) were presented with 95% confidence intervals (CIs).

Propensity score matching (PSM) was performed to reduce bias, according to the variables of FIGO stage, age, adjuvant treatment, parametrial involvement, LN metastasis, surgical margin, tumor size, histology, LVSI, and DSI. Matching was assessed by calculating the propensity scores before and after matching, *P*‐values \> 0.05 indicate the success of matching.

Sensitivity analyses included propensity score weighting (PSW) and multivariate Cox regression analyses. In PSW, we set the weight of the laparotomy group to 1/propensity score and the weight of the MIS to 1/1 -- propensity score.[^21^](#cam43287-bib-0021){ref-type="ref"} Absolute standardized differences less than 10% among variables indicated successful weighting. A multivariate Cox regression model was adjusted for same variables as in PSM.

Matching was performed in the stage IA1 (LVSI)‐IIA1 cohort, stage IB1 patient cohort, adjuvant treatment cohort, no‐adjuvant‐treatment cohort and each subgroup analysis for different combinations of various risk factors.

The statistical software packages used for analyses were SPSS (version 21.0; SPSS Inc, Chicago, IL, USA) and R 3.4.3(Vienna, Austria; [http://www.R‐project.org/](http://www.R-project.org/)). All tests were two‐sided, and *P* \< .05 was considered statistically significant.

3. RESULTS {#cam43287-sec-0011}
==========

The study selection schematic and sample matching processes are presented in Figures [1](#cam43287-fig-0001){ref-type="fig"}. In total, 3986 patients with stage IA1 (LVSI)‐IIA1 CC who underwent MIS (3173) or laparotomy (813) from 2006 to 2017 were finally enrolled as the study population. After sample matching using PSM and PSW, three independent cohorts, 3252 (IA1 (LVSI)‐IIA1 CC), 2161 (IB1 CC), and 3655 (adjuvant treatment and no‐adjuvant‐treatment group) patients were studied.

![Flowchart of patients included in this study. Abbreviations: CC, cervical cancer; MIS, minimally invasive surgery; OPEN, open radical hysterectomy; RRH, robot‐assisted radical hysterectomy; LRH, laparoscopic radical hysterectomy](CAM4-9-5908-g001){#cam43287-fig-0001}

3.1. Analysis of patients with stage IA1 (LVSI)‐IIA1 CC (cohort 1) {#cam43287-sec-0012}
------------------------------------------------------------------

### 3.1.1. Characteristics of the stage IA1 (LVSI)‐IIA1 CC cohort before and after matching {#cam43287-sec-0013}

Characteristics of the MIS and laparotomy groups in the stage IA1 (LVSI)‐IIA1 cohort before and after PSM are presented in Table [1](#cam43287-tbl-0001){ref-type="table"}. After matching, all variables were similar between MIS and laparotomy group. The matched cohort contained 3252 patients, including 2439 who underwent MIS and 813 who underwent laparotomy. The median follow‐up period of 90 (18‐162) months, during which 178 patients (129 MIS and 49 laparotomy) died and 237 (181 MIS and 56 laparotomy) experienced recurrences. In terms of the recurrence site, local recurrence occurred in 143 (60.3%) patients, and distant recurrence occurred in 94 (39.7%) patients. Among the 143 patients who experienced local recurrence, 102 (71.3%) received MIS and 41 (28.7%) received laparotomy. In patients with distant recurrence, 79 (84%) underwent MIS and 15 (16%) underwent laparotomy. Moreover, lung metastasis (38, 40.4%) was the most common distant metastasis.

###### 

Characteristics of stage A1(LVSI)‐ⅡA1 CC (cohort 1), before and after propensity‐score matching

  Characteristics                Before matching (*n* = 3986)   *P*          After matching (*n* = 3252)   *P*                        
  ------------------------------ ------------------------------ ------------ ----------------------------- ------------- ------------ -------
  **Age**                                                                                                                             
  Mean ± SD                      47.5 ± 9.6                     47.9 ± 9.4   0.313                         47.7 ± 9.8    47.9 ± 9.4   0.08
  **FIGO stage (%)**                                                                                                                  
  1A1 (LVSI)                     50 (1.6)                       9 (1.1)      0.002                         28 (1.1)      9 (1.1)      0.273
  1A2                            91 (2.9)                       21 (2.6)     54 (2.2)                      21 (2.6)                   
  1B1                            2260 (71.2)                    543 (66.8)   1683 (69)                     543 (66.8)                 
  1B2                            389 (12.3)                     99 (12.2)    325 (13.3)                    99 (12.2)                  
  2A1                            383 (12.1)                     141 (17.3)   349 (14.3)                    141 (17.3)                 
  **Comorbidity (%)**                                                                                                                 
  No                             2688 (84.7)                    688 (84.6)   0.949                         2049 (84)     688 (84.6)   0.677
  Yes                            485 (15.3)                     125 (15.4)   390 (16)                      125 (15.4)                 
  **Adjuvant treatment (%)**                                                                                                          
  No                             1404 (44.2)                    410 (50.4)   0.002                         1182 (48.5)   410 (50.4)   0.331
  Yes                            1769 (55.8)                    403 (49.6)   1257 (51.5)                   403 (49.6)                 
  **Tumor size, cm (%)**                                                                                                              
  ≤2                             1235 (38.9)                    305 (37.5)   0.137                         932 (38.2)    305 (37.5)   0.223
  (2,4\]                         1231 (38.8)                    345 (42.4)   961 (39.4)                    345 (42.4)                 
  \>4                            707 (22.3)                     163 (20)     546 (22.4)                    163 (20)                   
  **Histology (%)**                                                                                                                   
  SCC                            2425 (76.4)                    640 (78.7)   0.205                         1924 (78.9)   640 (78.7)   0.995
  AC                             379 (11.9)                     98 (12.1)    298 (12.2)                    98 (12.1)                  
  AS                             186 (5.9)                      43 (5.3)     124 (5.1)                     43 (5.3)                   
  Rare type                      30 (0.9)                       8 (1)        26 (1.1)                      8 (1)                      
  Unknown                        153 (4.8)                      24 (3)       67 (2.7)                      24 (3)                     
  **DSI (%)**                                                                                                                         
  Negative                       852 (26.9)                     181 (22.3)   0.026                         557 (22.8)    181 (22.3)   0.919
  \<2/3                          1005 (31.7)                    268 (33)     808 (33.1)                    268 (33)                   
  ≥2/3                           1316 (41.5)                    364 (44.8)   1074 (44)                     364 (44.8)                 
  **LVSI (%)**                                                                                                                        
  No                             1859 (57.6)                    501 (61.6)   0.116                         1497 (61.4)   501 (61.6)   0.901
  Yes                            1314 (41.4)                    312 (38.4)   942 (38.6)                    312 (38.4)                 
  **Surgical margin (%)**                                                                                                             
  No                             2951 (93)                      759 (93.4)   0.722                         2281 (93.5)   759 (93.4)   0.87
  Yes                            222 (7)                        54 (6.6)     158 (6.5)                     54 (6.6)                   
  **Parametrial invasion (%)**                                                                                                        
  No                             3024 (95.3)                    764 (94)     0.119                         2300 (94.3)   764 (94)     0.729
  Yes                            149 (4.7)                      49 (6)       139 (5.7)                     49 (6)                     
  **LN metastasis (%)**                                                                                                               
  No                             2659 (83.8)                    647 (79.6)   0.004                         1982 (81.3)   647 (79.6)   0.292
  Yes                            514 (16.2)                     166 (20.4)   457 (18.7)                    166 (20.4)                 
  **Metastasis site (%)**                                                                                                             
  No                             2659 (83.8)                    647 (79.6)   0.034                         1982 (81.3)   647 (79.6)   0.607
  Pelvic LN                      386 (12.2)                     129 (15.9)   341 (14)                      129 (15.9)                 
  Common iliac LN                106 (3.3)                      31 (3.8)     95 (3.9)                      31 (3.8)                   
  Para‐aortic LN                 22 (0.7)                       6 (0.7)      21 (0.9)                      6 (0.7)                    

Abbreviations: AC, adenocarcinoma; AS, adenosquamous carcinoma; CC, cervical cancer; DSI, deep stromal invasion; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; LVSI, lymphovascular space incision; MIS, minimally invasive surgery; OPEN, open radical hysterectomy; SCC, squamous cell carcinoma; SD, standard deviation.
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### 3.1.2. Analysis in matched patients with stage IA1 (LVSI)‐IIA1 CC {#cam43287-sec-0014}

In the matched stage IA1 (LVSI)‐IIA1 CC cohort, the MIS and laparotomy groups showed similar 2‐year or 5‐year RFS and OS (2‐year RFS, 1.04 \[0.76, 1.42\], *P* = .807; 2‐year OS, 0.99 \[0.70, 1.41\], *P* = .956; 5‐year RFS, 1.12 \[0.76, 1.65\], *P* = .570; 5‐year OS, 1.20 \[0.79, 1.83\], *P* = .387) in all three analyses, including PSM (Figures [2A‐D](#cam43287-fig-0002){ref-type="fig"}), PSW (Figure [S1](#cam43287-sup-0001){ref-type="supplementary-material"}A‐D) and multivariate Cox regression analyses. Additionally, we divided the MIS group into the robot‐assisted radical hysterectomy (RRH) and laparoscopic radical hysterectomy (LRH) (Figures [1E‐H](#cam43287-fig-0001){ref-type="fig"}). After matching (Table [S2](#cam43287-sup-0006){ref-type="supplementary-material"}), no differences were observed in RFS and OS neither between the RRH and laparotomy groups (RFS, 1.546 \[0.867, 2.755\], *P* = .14; OS, 1.326 \[0.593, 2.959\], *P* = .492) or between the LRH and laparotomy groups (RFS, 0.993 \[0.725, 1.361\], *P* = .965; OS, 1.013 \[0.714, 1.437\], *P* = .942). Nevertheless, we wondered whether some differences in survival outcomes might exist between the MIS and laparotomy groups when patients were stratified by subgroups. Therefore, we performed the subgroup analyses described below.

![Survival outcome comparisons for matched patients. FIGO stage A1(LVSI)‐ⅡA1 cohort (A‐H); FIGO stage ⅠB1cohort (I‐L). Recurrence‐free survival (A, C, E, G, I, K); Overall survival (B, D, F, H, J, L). 2‐year (A, B, E‐H, I, J); 5‐year (C, D, K, L). Abbreviations: MIS, minimally invasive surgery; OPEN, open radical hysterectomy; RRH, robot‐assisted radical hysterectomy; LRH, laparoscopic radical hysterectomy](CAM4-9-5908-g002){#cam43287-fig-0002}

### 3.1.3. Subgroup analysis in matched patients with stage IA1 (LVSI)‐IIA1 CC {#cam43287-sec-0015}

A subgroup analysis was then performed in the matched stage IA1 (LVSI)‐IIA1 cohort according to age, FIGO stage, comorbidity, and adjuvant treatment (Figures [3A and B](#cam43287-fig-0003){ref-type="fig"}). We identified poorer RFS (HR, 1.691 \[1.017, 2.814\], *P* = .04) for patients with stage IB1 who underwent MIS, whereas the OS was similar between patients who underwent MIS and laparotomy. In terms of adjuvant treatment, the MIS group exhibited a worse RFS (HR 2.34, *P* = .02) and similar OS to the laparotomy group for patients treated without adjuvant treatment, while the RFS and OS were similar between the two groups for patients treated with adjuvant treatment.

Additionally, we also performed a more comprehensive subgroup analysis according to intermediated/high‐risk factors (Table [S3](#cam43287-sup-0006){ref-type="supplementary-material"}). Three high‐risk factors (surgical margin, LN metastasis and parametrial involvement) and four intermediate‐risk factors (tumor size, DSI, LVSI and histology) formed 11 different combinations of subgroups. Matching was performed in each subgroup. Interestingly, we identified a poorer RFS of MIS for patients with any one factor among (\>2 cm, LVSI, DSI, non‐SCC (squamous cell carcinoma)). However, no difference between MIS and laparotomy were found for patients with more risk factors.

Based on these findings, MIS might result in poor survival outcomes in patients with stage IB1, without adjuvant treatment and even less risk factors. Therefore, we focused on the stage IB1 cohort and adjuvant‐treatment cohort in the subsequent study to confirm the robustness of our findings.

![Subgroup analysis. FIGO stage A1(LVSI)‐ⅡA1 cohort (A‐B); FIGO stage B1cohort (C‐D). Recurrence‐free survival (A, C); Overall survival (B, D). Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; AC, adenocarcinoma; AS, adenosquamous carcinoma; DSI, deep stromal invasion; LVSI, lymphovascular space incision](CAM4-9-5908-g003){#cam43287-fig-0003}

3.2. Analysis of patients with stage IB1 CC (cohort 2) {#cam43287-sec-0016}
------------------------------------------------------

### 3.2.1. Characteristics of the stage IB1 CC cohort before and after matching {#cam43287-sec-0017}

Because higher recurrence risk was observed for MIS in the stage IB1 subgroup, we therefore performed a deep analysis (Table [2](#cam43287-tbl-0002){ref-type="table"}). Before matching, the proportion of patients treated with adjuvant treatment was greater in the MIS group, while LN metastasis was less common in the MIS group. After matching, no significant differences in all variables were observed between the two groups. In the matched stage IB1 cohort, 2172 patients were analyzed (1629 MIS and 543 laparotomy). One hundred twenty‐three recurrences (104 MIS and 19 laparotomy) and 83 deaths (69 MIS and 14 laparotomy) occurred.

###### 

Characteristics of stage B1 CC (cohort 2), before and after propensity‐score matching

  Characteristics                Before matching (*n* = 2803)   *P*          After matching (*n* = 2172)   *P*                       
  ------------------------------ ------------------------------ ------------ ----------------------------- ------------ ------------ -------
  **Age**                                                                                                                            
  Mean ± SD                      47.1 ± 9.5                     47.4 ± 9.4   0.380                         47.3 ± 9.4   47.4 ± 9.4   0.577
  **Comorbidity (%)**                                                                                                                
  No                             1911 (84.6)                    468 (86.2)   0.341                         1368(84)     468(86.2)    0.217
  Yes                            349 (15.4)                     75 (13.8)    261(16)                       75(13.8)                  
  **Adjuvant treatment (%)**                                                                                                         
  No                             1101 (48.7)                    301 (55.4)   0.005                         881(54.1)    301(55.4)    0.584
  Yes                            1159 (51.3)                    242 (44.6)   748(45.9)                     242(44.6)                 
  **Tumor size, cm (%)**                                                                                                             
  ≤2                             1026(45.4)                     236(43.5)    0.450                         699(42.9)    236(43.5)    0.973
  (2,4\]                         894(39.6)                      214(39.4)    650(39.9)                     214(39.4)                 
  \>4                            340(15)                        93(17.1)     280(17.2)                     93(17.1)                  
  **Histology (%)**                                                                                                                  
  SCC                            1668(73.8)                     420(77.3)    0.208                         1229(75.4)   420(77.3)    0.467
  AC                             316(14)                        71(13.1)     249(15.3)                     71(13.1)                  
  AS                             137(6.1)                       29(5.3)      98(6)                         29(5.3)                   
  Rare type                      24(1.1)                        7(1.3)       12(0.7)                       7(1.3)                    
  Unknown                        115(5.1)                       16(2.9)      41(2.5)                       16(2.9)                   
  **DSI (%)**                                                                                                                        
  Negative                       651(28.8)                      133(24.5)    0.131                         381(23.4)    133(24.5)    0.814
  \<2/3                          800(35.4)                      202(37.2)    628(38.6)                     202(37.2)                 
  ≥2/3                           809(35.8)                      208(38.3)    620(38.1)                     208(38.3)                 
  **LVSI (%)**                                                                                                                       
  No                             1365(60.4)                     345(63.5)    0.178                         1029(63.2)   345(63.5)    0.877
  Yes                            895(39.6)                      198(36.5)    600(36.8)                     198(36.5)                 
  **Surgical margin (%)**                                                                                                            
  No                             2143 (94.8)                    517 (95.2)   0.712                         1549(95.1)   517(95.2)    0.908
  Yes                            117 (5.2)                      26 (4.8)     80(4.9)                       26(4.8)                   
  **Parametrial invasion (%)**                                                                                                       
  No                             2189 (96.9)                    526 (96.9)   0.99                          1570(96.4)   526(96.9)    0.59
  Yes                            71 (3.1)                       17 (3.1)     59(3.6)                       17(3.1)                   
  **LN metastasis (%)**                                                                                                              
  No                             1967(87)                       450(82.9)    0.11                          1359(83.4)   450(82.9)    0.765
  Yes                            293(13)                        93(17.1)     270(16.6)                     93(17.1)                  
  **Metastasis site (%)**                                                                                                            
  No                             1967(87)                       450(82.9)    0.076                         1359(83.4)   450(82.9)    0.948
  Pelvic LN                      228(10.1)                      74(13.6)     211(13)                       74(13.6)                  
  Common iliac LN                51(2.3)                        16(2.9)      47(2.9)                       16(2.9)                   
  Para‐aortic LN                 14(0.6)                        3(0.6)       12(0.7)                       3(0.6)                    

Abbreviations: AC, adenocarcinoma; AS, adenosquamous carcinoma; CC, cervical cancer; DSI, deep stromal invasion; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph nodeLVSI, lymphovascular space incision; MIS, minimally invasive surgery; OPEN, open radical hysterectomy; SCC, squamous cell carcinoma; SD, standard deviation.
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### 3.2.2. Deep analysis in matched patients with stage IB1 CC {#cam43287-sec-0018}

In the matched stage IB1 cohort (Figure [2I‐L](#cam43287-fig-0002){ref-type="fig"}), MIS resulted in a poorer 2‐year (RFS, HR 1.81 \[1.085, 3.003\], *P* = .023; OS, HR 1.87 \[1.025, 3.401\], *P* = .041) and 5‐year RFS and OS (RFS, HR 2.17 \[1.212, 3.891\], *P* = .009; OS, HR 2.57 \[1.294, 5.102\], *P* = .007).

PSW and multivariate Cox regression analyses were performed to test the robustness of our results. In the propensity‐weighted cohort, all covariates were balanced, with SDs less than 10% (Figure [S2](#cam43287-sup-0002){ref-type="supplementary-material"}) and *P*‐values \> 0.05. Kaplan‐Meier curves showed inferior RFS and OS for the MIS group compared to the laparotomy group (RFS, HR 1.6, *P* = .025; OS, HR 1.79, *P* = .018) (Figure [S1](#cam43287-sup-0001){ref-type="supplementary-material"}E‐H). The multivariate Cox regression analysis yielded consistent results (RFS, HR 1.65, *P* = .048; OS HR 1.88, *P* = .037). Altogether, these three methods reveal a higher risk of recurrence and death in patients with stage IB1 CC who underwent MIS than in the laparotomy group.

### 3.2.3. Subgroup analysis in matched patients with stage IB1 CC {#cam43287-sec-0019}

Next, we performed a subgroup analysis of the matched stage IB1 CC cohort (Figures [3C and D](#cam43287-fig-0003){ref-type="fig"}). The MIS group showed worse RFS and OS than the laparotomy group in the following subgroups: a) negative parametrial involvement (RFS, *P* = .03; OS, *P* = .04); b) negative surgical margin (RFS, *P* = .005; OS, *P* = .006); c) negative LN metastasis (RFS, *P* = .03; OS, *P* = .04) and d) DSI \< 2/3 (RFS, *P* = .04; OS, *P* = .03). In terms of tumor size, patients with tumor size \> 4 cm showed an inferior RFS (HR 3.58, *P* = .01) in MIS, whereas the OS was similar between two groups.

In the analysis of the histological type, poorer RFS and OS were observed for patients with SCC in the MIS group (RFS, HR 2.22, *P* = .02; OS, HR 2.31, *P* = .04), whereas similar RFS and OS were observed in patients with adenocarcinoma (AC) or adenosquamous carcinoma (AS) between two groups. In addition, consistent with the results obtained for the stage IA1 (LVSI)‐IIA1 cohort, a higher recurrence risk was observed for patients in the no‐adjuvant‐treatment group who received MIS (RFS, HR 5.85, *P* = .006), whereas no significant differences between MIS and laparotomy were observed in the adjuvant‐treatment group.

In conclusion, MIS resulted in poor survival outcomes in many subgroups of the stage IB1 CC cohort, such as SCC histology, no‐adjuvant‐treatment group and even certain low‐risk subgroups.

3.3. Analysis of surgical approach‐related survival outcomes in patients treated with or without adjuvant treatment (cohort 3) {#cam43287-sec-0020}
------------------------------------------------------------------------------------------------------------------------------

Because a higher recurrence risk was observed in patients who were not treated with adjuvant treatment in the matched stage IA1 (LVSI)‐IIA1 and stage IB1 cohorts who underwent MIS, we therefore focused on patients treated with or without adjuvant treatment and performed a deep analysis. Before matching (Table [S4](#cam43287-sup-0006){ref-type="supplementary-material"}), 2172 patients, predominantly with stage IB1‐IIA1 CC (2138, 98.4%), received adjuvant treatment (1769 MIS and 403 laparotomy) while 1814 (1404 MIS and 410 laparotomy) did not receive further treatment. Concurrent chemoradiation therapy (CCRT) (1427) was the most common type, followed by chemotherapy and radiotherapy. Patients in the adjuvant‐treatment group had more risk factors than patients in the no‐adjuvant‐treatment group.

In matched adjuvant‐treatment cohort, all variables other than LN metastasis were similar between the MIS and laparotomy groups (Table [S5](#cam43287-sup-0006){ref-type="supplementary-material"}). In the survival analysis, neither PSM nor multivariate analyses identified differences in RFS and OS between the MIS and laparotomy groups (RFS, *P* = .051; OS, *P* = .087) (Figure [S3](#cam43287-sup-0003){ref-type="supplementary-material"}).

In the matched no‐adjuvant‐treatment cohort, with the exception of the FIGO stage, tumor size and DSI, all variables were similar between the two groups (Table [S5](#cam43287-sup-0006){ref-type="supplementary-material"}). Consistent with the result of subgroup analyses of both the stage IA1 (LVSI)‐IIA1 and stage IB1 cohorts, both PSM and multivariate analyses revealed a worse RFS for the MIS group than the laparotomy group (HR 2.24, *P* = .033) in the no‐adjuvant‐treatment cohort, whereas the OS was similar in the MIS and laparotomy groups (Figure [S3](#cam43287-sup-0003){ref-type="supplementary-material"}).

Therefore, we concluded that patients with stage IA1 (LVSI)‐IIA1 CC who received MIS had a higher recurrence risk than patients who received laparotomy in the no‐adjuvant‐treatment cohort. However, in patients treated with adjuvant treatment, the survival outcomes of MIS and laparotomy were similar.

3.4. Analysis of temporal trends and surgeon proficiency in the surgical approach {#cam43287-sec-0021}
---------------------------------------------------------------------------------

The trends of MIS and laparotomy between 2003 and 2017 are shown in Figure [S4](#cam43287-sup-0004){ref-type="supplementary-material"}. The use of MIS significantly increased from 0% in 2003 to 99.42% in 2017, and MIS became the dominant surgery approach used since 2010 (52.79%).

We also analyze the effect of surgeon proficiency (skilled/unskilled) on survival outcomes in the MIS and laparotomy groups. Significant differences in vital variables were not identified between skilled and unskilled groups (Table [S6](#cam43287-sup-0006){ref-type="supplementary-material"}). In the survival analysis, poorer RFS and OS were observed in the unskilled group (RFS, HR 6.274, *P* \< .01; OS, HR 5.195, *P* \< .01). When stratified according to the surgical approach, we noticed an inferior RFS and OS of patients who underwent MIS in the unskilled group (RFS, HR 7.346, *P* \< .01; OS, HR 6.161, *P* \< .01). However, differences were not observed in the survival of patients who received laparotomy between the skilled and unskilled groups (Figure [S5](#cam43287-sup-0005){ref-type="supplementary-material"}). Thus, inadequate surgeon proficiency strongly correlated with poor RFS and OS in patients who underwent MIS, but not in patients who underwent laparotomy.

3.5. Univariate and multivariate analyses of patients with stage IA1 (LVSI)‐IIA1 CC {#cam43287-sec-0022}
-----------------------------------------------------------------------------------

We next performed univariate and multivariate Cox analyses of the stage IA1 (LVSI)‐IIA1 CC to investigate the comprehensive prognostic factors for RFS or OS (Table [3](#cam43287-tbl-0003){ref-type="table"}). According to the univariate analysis, with the exception of age, comorbidity and surgical approach, all variables showed *P* values \< 0.05 for both RFS and OS. LN metastasis, parametrial involvement, DSI, histology and FIGO stage were identified as independent prognostic factors for a poor RFS in the multivariate analysis. The FIGO stage, LN metastasis, surgical margin, DSI, and histology were identified as independent prognostic factors for a poor OS.

###### 

Factors associated with recurrence‐free survival and overall survival in stage A1(LVSI)‐ⅡA1 CC patients

  Characteristics               No.    RFS                      OS                                                                                                    
  ----------------------------- ------ ------------------------ --------- ----------------------- --------- ----------------------- --------- ----------------------- ---------
  Age                                                                                                                                                                 
  \<50                          2379   1                        0.072                                       1                       0.076                             
  ≥50                           1607   1.265\[0.979,1.634\]                                                 1.307\[0.972,1.757\]                                      
  FIGO (%)                                                      \<0.001                           \<0.001                           \<0.001                           \<0.001
  1A1 (LVSI)                    59     1                                  1                                 1                                 1                       
  1A2                           112    0.338\[0.056,2.023\]               0.517\[0.086,3.119\]              0.518\[0.073,3.679\]              0.823\[0.114,5.925\]    
  1B1                           2803   0.827\[0.263,2.601\]               0.693\[0.218,2.2\]                0.821\[0.202,3.339\]              0.67\[0.164,2.741\]     
  1B2                           488    2.365\[0.741,7.549\]               1.45\[0.45,4.674\]                3.46\[0.845,14.175\]              2.091\[0.508,8.609\]    
  2A1                           524    1.984\[0.619,6.356\]               1.119\[0.345,3.629\]              2.059\[0.494,8.572\]              1.138\[0.271,4.778\]    
  Comorbidity (%)                                               0.658                                                               0.275                             
  No                            3376   1                                                                    1                                                         
  Yes                           610    1.087\[0.752,1.57\]                                                  1.241\[0.842,1.829\]                                      
  Surgery approach (%)                                          0.89                                                                0.936                             
  MIS                           3173   1                                                                    1                                                         
  OPEN                          813    1.022\[0.753,1.385\]                                                 1.014\[0.722,1.424\]                                      
  Adjuvant treatment (%)                                        \<0.001                                                             \<0.001                           
  No                            1814   1                                                                    1                                                         
  Yes                           2172   2.309\[1.734,3.076\]                                                 2.454\[1.754,3.432\]                                      
  Tumor size, cm (%)                                            \<0.001                                                             \<0.001                           
  ≤2                            1540   1                                                                    1                                                         
  (2,4\]                        1576   1.978\[1.399,2.797\]                                                 1.909\[1.27,2.87\]                                        
  \>4                           870    3.737\[2.637,5.295\]                                                 4.366\[2.922,6.524\]                                      
  Histology (%)                                                 \<0.001                           \<0.001                           \<0.001                           \<0.001
  SCC                           3065   1                                  1                                 1                                 1                       
  AC                            477    1.6\[1.138,2.251\]                 1.763\[1.248,2.489\]              1.904\[1.308,2.772\]              2.078\[1.423,3.035\]    
  AS                            229    1.399\[0.849,2.303\]\]             1.347\[0.816,2.224\]              1.534\[0.866,2.718\]              1.454\[0.818,2.584\]    
  Rare type                     38     5.039\[2.575,9.86\]                5.108\[2.602,10.028\]             4.138\[1.691,10.127\]             4.896\[1.991,12.038\]   
  Unknown                       177    0.112\[0.016,0.797\]               0.321\[0.044,2.366\]              0.189\[0.026,1.352\]              0.638\[0.085,4.765\]    
  DSI (%)                                                       \<0.001                           \<0.001                           \<0.001                           \<0.001
  Negative                      1033   1                                  1                                 1                                 1                       
  \<2/3                         1273   1.922\[1.141,3.238\]               1.519\[0.891,2.591\]              2.483\[1.261,4.889\]              2.027\[1.01,4.068\]     
  ≥2/3                          1680   5.346\[3.363,8.498\]               3.12\[1.915,5.085\]               7.315\[3.954,13.533\]             4.173\[2.184,7.973\]    
  LVSI (%)                                                      \<0.001                                                             \<0.001                           
  No                            2360   1                                                                    1                                                         
  Yes                           1626   2.049\[1.583,2.65\]                                                  2.289\[1.697,3.087\]                                      
  Surgical margin (%)                                           \<0.001                           0.061                             \<0.001                           0.015
  No                            3710   1                                  1                                 1                                 1                       
  Yes                           276    2.301\[1.593,3.325\]               1.449\[0.982,2.137\]              2.503\[1.65,3.796\]               1.705\[1.109,2.623\]    
  Parametrial involvement (%)                                   \<0.001                           0.028                             \<0.001                           
  No                            3788   1                                  1                                 1                                                         
  Yes                           198    3.484\[2.421,5.007\]               1.559\[1.05,2.316\]               3.25\[2.114,4.998\]                                       
  LN metastasis (%)                                             \<0.001                           \<0.001                           \<0.001                           \<0.001
  No                            3306   1                                  1                                 1                                 1                       
  Yes                           680    3.282\[2.527,4.262\]               1.928\[1.45,2.565\]               3.64\[2.7,4.908\]                 2.241\[1.635,3.071\]    

Abbreviations: AC, adenocarcinoma; AS, adenosquamous carcinoma; CC, cervical cancer; DSI, deep stromal invasion; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; LVSI, lymphovascular space incision; MIS, minimally invasive surgery; OPEN, open radical hysterectomy; SCC, squamous cell carcinoma; SD, standard deviation.
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4. DISCUSSION {#cam43287-sec-0023}
=============

In this study, we evaluated the survival outcomes of 3986 patients with FIGO stage IA1 (LVSI)‐IIA1 CC who underwent radical hysterectomy via MIS and laparotomy. (1) The 2‐ and 5‐year RFS (2‐year, hazard ratio \[HR\], 1.81; 95% confidence interval \[CI\], 1.09‐3.0; 5‐year, HR, 2.17; 95% CI, 1.21‐3.89) or OS (2‐year, HR, 1.87; 95% CI, 1.03‐3.40; 5‐year, HR, 2.57; 95% CI, 1.29‐5.10) were significantly worse for MIS in patients with stage I B1, but not the cohort overall (2‐year RFS, HR, 1.04; 95% CI, 0.76‐1.42; 2‐year OS, HR, 0.99; 95% CI, 0.70‐1.41; 5‐year RFS, HR, 1.12; 95% CI, 0.76‐1.65; 5‐year OS, HR, 1.20; 95% CI, 0.79‐1.83) or other stages (2) In a subgroup analysis, MIS exhibited poorer survival in many population subsets, even in patients with less risk factors, such as patients with squamous cell carcinoma, negative for parametrial involvement, with negative surgical margins, negative for lymph node metastasis, and deep stromal invasion \< 2/3. (3) In the cohort treated with or without adjuvant treatment, MIS resulted in a worse RFS than laparotomy in patients treated without adjuvant treatment, whereas no differences in RFS and OS were observed in patients treated with adjuvant treatment. (4) Inadequate surgeon proficiency strongly correlated with poor RFS and OS in patients who underwent MIS than in patients who underwent laparotomy.

After a decade of widespread acceptance of MIS, the results of the LACC upended the previous consensus. However, some results from the trial remain controversial, including early termination, inadequate pathological review, and follow‐up data, the dominant RRH trend in the United States,[^22^](#cam43287-bib-0022){ref-type="ref"} and the lack of an assessment of surgeon proficiency. Based on recently emerging new evidence,[^10^](#cam43287-bib-0010){ref-type="ref"}, [^11^](#cam43287-bib-0011){ref-type="ref"}, [^23^](#cam43287-bib-0023){ref-type="ref"}, [^24^](#cam43287-bib-0024){ref-type="ref"}, [^25^](#cam43287-bib-0025){ref-type="ref"}, [^26^](#cam43287-bib-0026){ref-type="ref"}, [^27^](#cam43287-bib-0027){ref-type="ref"}, [^28^](#cam43287-bib-0028){ref-type="ref"}, [^29^](#cam43287-bib-0029){ref-type="ref"} with the exception of the findings reported by Doo et al[^29^](#cam43287-bib-0029){ref-type="ref"} and Alfonzo et al[^28^](#cam43287-bib-0028){ref-type="ref"} which provide no evidence that MIS results in an inferior survival outcome compared to laparotomy, most studies reported consistent results with the LACC. Nevertheless, the majority of those studies were small sample size and lack of a comprehensive subgroup analysis of crucial pathological factors. Therefore, we performed this multicenter matched study to provide additional evidence in support of previous studies.

Consistent with the findings reported by Cusimano et al[^11^](#cam43287-bib-0011){ref-type="ref"} we observed inferior RFS and OS for patients with stage IB1 CC who underwent MIS compared to the laparotomy group. These findings were verified using various methods, including PSM, PSW and multivariate Cox regression analyses. In addition, by performing a subgroup analysis, we observed poorer survival outcomes for patients who received MIS in various population subgroups, including the SCC subgroup and certain low‐risk subgroups, such as patients with negative parametrial involvement, negative surgical margins, negative LN metastasis, DSI \< 2/3, etc Patients with CC presenting with high/intermediate risk factors should receive adjuvant treatment, according to the NCCN guidelines. Therefore, the explanation for the lack of differences between MIS and laparotomy in patients with high‐risk factors may potentially be the adjuvant treatment, which might mask the poor performance of MIS. Notably, in terms of adjuvant treatment, our results indeed showed similar RFS and OS were observed in patients treated with adjuvant treatment in the MIS and laparotomy groups, but inferior RFS was observed in patients treated without adjuvant treatment in the MIS group compared to the laparotomy group. Admittedly, these results should be further confirmed in future prospective studies with large sample sizes.

In the current study, a higher risk of recurrence and death was observed in various population subgroups who underwent MIS. The possible explanations include a) the use of a uterine manipulator might crush the cervical tumor and lead to dissemination, (b) the intracorporeal colpotomy might cause tumor implantation metastasis in the pelvic cavity in the abdomen, and (c) CO~2~ levels in the pneumoperitoneum might adversely affect the survival outcome by accelerating tumor growth and spread.[^30^](#cam43287-bib-0030){ref-type="ref"} (d) Although many previous studies showed short‐term benefits of MIS, including shorter hospital stays and fewer infections, etc, some emerging new evidence suggested an association between MIS and a higher risk of major surgical complications than laparotomy.[^12^](#cam43287-bib-0012){ref-type="ref"} Despite these possible explanations, based on our findings, inadequate surgeon proficiency might also exert an adverse effect on survival outcomes. Patients who underwent MIS performed by an unskilled surgeon displayed significantly worse RFS and OS than patients who received an operation by a skilled surgeon, while no differences were observed in patients who underwent laparotomy. Thus, inadequate surgeon proficiency strongly correlated with poor RFS and OS in patients who underwent MIS, but not in patients who underwent laparotomy.

Consistent with previous studies,[^10^](#cam43287-bib-0010){ref-type="ref"} the MIS group showed worse RFS and OS than the laparotomy group in patients with SCC, whereas no difference was observed in patients without SCC. Adenocarcinoma, one of the most common types of non‐SCC tumors, is mainly a multifocal lesion that is difficult to detect when it occurs at a high level in the cervical canal, and it is known to have a worse prognosis than SCC. However, the aggressive nature of non‐SCC may mask the poor performance of MIS. In addition, due to the endophytic behavior, it is less likely to affect the tumor‐free principle of MIS. All these possibilities might explain the different performance of MIS and laparotomy in terms of patients with different histological types of CC.

Some limitations of our study are listed below. First, although we strictly adhered to the inclusion and exclusion criteria, bias might still exist due to the retrospective study design and large time span. Second, heterogeneity might exist among our four hospitals. Third, the relatively small number of patients with stage IA, IB2 and IIA1 CC limited our power to detect differences between MIS and laparotomy. Thus, stricter quality control measures and more evidence on those stages obtained with new pathology‐based FIGO criteria are needed. These limitations might be overcome in future prospective studies.

Notably, our study has several strengths. First, to our knowledge, this study is the first to perform a comprehensive subgroup analysis on different combinations of various intermediate/high‐risk factors, such as the histological type, DSI and LVSI. Second, this study is analyzed the largest multicenter cohort with the longest follow‐up reported to date for the survival outcomes based on real world evidence. Third, various matching methods were performed to reduce bias, including PSM, PSW and multivariate Cox analyses; the consistent results obtained using all methods confirmed the robustness. Finally, we separately compared RRH or LRH with laparotomy.

In conclusion, our four‐center matched cohort study identified an association of MIS with inferior RFS and OS compared to laparotomy in patients with stage IB1 CC and various population subgroups, including the SCC subgroup and certain low‐risk subgroups. Moreover, MIS resulted in a worse RFS in patients treated with adjuvant treatment, whereas no differences in RFS and OS were observed in patients treated without adjuvant treatment. Additionally, inadequate surgeon proficiency strongly correlated with poor RFS and OS in patients who underwent MIS, but not laparotomy. Considering the poor survival outcomes of MIS in various population subgroups, laparotomy might be the recommended approach for patients with CC.
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